Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
8,213 results
  • Biosimilars for the treatment of psoriatic arthritis. [Journal Article]
    Expert Rev Clin Immunol 2019Cantini F, Benucci M, … Niccoli L
  • Introduction: In recent years, biosimilars of reference adalimumab (re-ADA), etanercept (re-ETN) and infliximab (re-IFX) have been licensed. In absence of specific controlled studies, by the extrapolation principle, biosimilars have been approved for the treatment of psoriatic arthritis (PsA). Areas covered: To assess the efficacy and safety of biosimilars in PsA, the literature, present until Ju…
  • [Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report]. [Journal Article]
    Beijing Da Xue Xue Bao Yi Xue Ban 2019; 51(5):977-980Zhang S, Liu XY, … Zhou C
  • Among the various drug induced dermatological entities toxic epidermalnecrolysis (TEN) and Stevens-Johnson syndrome (SJS) occupy a primary place in terms of mortality. Toxic epidermal necrolysis also known as Lyell's syndrome was first described by Lyell in 1956. Drugs are by far the most common cause of toxic epidermal necrolysis, in which large sheets of skin are lost from the body surface maki…
  • Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. [Journal Article]
    Expert Opin Drug Metab Toxicol 2019Campanati A, Paolinelli M, … Offidani A
  • Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction…
  • Is TNF Inhibitor Exposure a Risk Factor for Amyotrophic Lateral Sclerosis? [Editorial]
    Fundam Clin Pharmacol 2019Bougea A
  • In September 1992, Marc Feldmann announced publicly the grand success of 'infliximab', the Centocor's TNF alpha inhibitors anti-TNF (TNFi), in a meeting held by David Naor in Israel [1]. Clinical data remarkably showed that no new forms of erosion have emerged, as opposed to any previous Rheumatoid Arthritis (RA) treating drugs [2]. Οther auto immune diseases such as Crohn's disease, systemic vas…
  • The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. [Journal Article]
    Rheumatology (Oxford) 2019Davies R, Cock D, … British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) and the Biologics for Children with Rheumatic Diseases (BCRD) study
  • CONCLUSIONS: In this first paper to compare the rate of new onset uveitis across the three main anti-TNF therapies used in JIA, a new diagnosis of uveitis is less common among patients starting biologics compared with MTX, although this did not reach statistical significance. The suggested protective effect of etanercept is likely explained by confounding, whereby patients in the MTX cohort are younger and earlier in disease, and therefore at greater risk of developing uveitis compared with etanercept patients.
New Search Next